Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicentre, Randomised, Double-blinded, Parallel Group, Placebo Controlled Clinical Study for Evaluating the Efficacy of EGb 761® (Tanakan®) (240mg) in the Recovery of Neurological Impairment Following Ischemic Stroke

NCT00276380 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00276380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00276380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicentre, Randomised, Double-blinded, Parallel Group, Placebo Controlled Clinical Study for Evaluating the Efficacy of EGb 761® (Tanakan®) (240mg) in the Recovery of Neurological Impairment Following Ischemic Stroke
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2003
Completion date
March 31, 2009
Enrollment
204 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

neurological impairment, stroke, acute